<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Oncogenesis</journal-id>
    <journal-id journal-id-type="iso-abbrev">Oncogenesis</journal-id>
    <journal-title-group>
      <journal-title>Oncogenesis</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2157-9024</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10202962</article-id>
    <article-id pub-id-type="pmid">37217468</article-id>
    <article-id pub-id-type="publisher-id">476</article-id>
    <article-id pub-id-type="doi">10.1038/s41389-023-00476-0</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Circlehunter: a tool to identify extrachromosomal circular DNA from ATAC-Seq data</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9068-6111</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Manqiu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Shufan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jiang</surname>
          <given-names>Rong</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9600-2171</contrib-id>
        <name>
          <surname>Chen</surname>
          <given-names>Shaomu</given-names>
        </name>
        <address>
          <email>chenshaomu@suda.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5543-9334</contrib-id>
        <name>
          <surname>Huang</surname>
          <given-names>Moli</given-names>
        </name>
        <address>
          <email>huangml@suda.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.263761.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0198 0694</institution-id><institution>School of Biology and Basic Medical Sciences, </institution><institution> Soochow University, </institution></institution-wrap>215123 Suzhou, China </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.429222.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0228</institution-id><institution>Department of Thoracic Surgery, </institution><institution>The First Affiliated Hospital of Soochow University, </institution></institution-wrap>215006 Suzhou, China </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>22</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>12</volume>
    <issue>1</issue>
    <elocation-id>28</elocation-id>
    <history>
      <date date-type="received">
        <day>5</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>4</day>
        <month>5</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>5</day>
        <month>5</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">In cancer, extrachromosomal circular DNA (ecDNA), or megabase-pair amplified circular DNA, plays an essential role in intercellular heterogeneity and tumor cell revolution because of its non-Mendelian inheritance. We developed circlehunter (<ext-link ext-link-type="uri" xlink:href="https://github.com/suda-huanglab/circlehunter">https://github.com/suda-huanglab/circlehunter</ext-link>), a tool for identifying ecDNA from ATAC-Seq data using the enhanced chromatin accessibility of ecDNA. Using simulated data, we showed that circlehunter has an F1 score of 0.93 at 30× local depth and read lengths as short as 35 bp. Based on 1312 ecDNAs predicted from 94 publicly available datasets of ATAC-Seq assays, we found 37 oncogenes contained in these ecDNAs with amplification characteristics. In small cell lung cancer cell lines, ecDNA containing <italic>MYC</italic> leads to amplification of <italic>MYC</italic> and cis-regulates the expression of <italic>NEUROD1</italic>, resulting in an expression pattern consistent with the <italic>NEUROD1</italic> high expression subtype and sensitive to Aurora kinase inhibitors. This showcases that circlehunter could serve as a valuable pipeline for the investigation of tumorigenesis.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Cancer genomics</kwd>
      <kwd>Small-cell lung cancer</kwd>
      <kwd>Gene amplification</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id>
            <institution>National Natural Science Foundation of China (National Science Foundation of China)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>31971117</award-id>
        <principal-award-recipient>
          <name>
            <surname>Huang</surname>
            <given-names>Moli</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>National Key R&amp;D Program of China [2018YFA0801100] Natural Science Foundation of Suzhou [SYS201517] Priority Academic Program Development of Jiangsu Higher Education Institutions</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© Springer Nature America, Inc. 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Introduction</title>
    <p id="Par2">Extrachromosomal circular DNA (ecDNA) is circular DNA molecules outside the chromosome [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In contrast to microDNA, the common, seemingly small, and gene-free, consisting primarily of 200–500 bp repetitive DNA fragments found in eukaryotes. ecDNA is typically found only in cancer samples, typically has a size over 1 million base pairs, and contains both genes and noncoding DNA, including regulatory regions [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Since it was first reported in 1965 [<xref ref-type="bibr" rid="CR8">8</xref>], an increasing number of ecDNAs have been found to carry important oncogenes in different types of cancer [<xref ref-type="bibr" rid="CR9">9</xref>], including <italic>MYC</italic>, <italic>MYCN</italic>, and <italic>EGFR</italic> [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. Since ecDNA lacks centromeres, they may segregate randomly during mitosis, and the resulting amplification of oncogenes enables cancer cells to rapidly acquire evolutionary fitness and drug resistance [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. In addition to the high copy number due to gene amplification, the increased accessibility due to reduced nucleosome wrapping, and the proximity of cis-regulatory elements due to circularization, increased the expression level of oncogenes on ecDNA to the top 1% in the whole transcriptome and contributed to the pathogenesis of tumors [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Currently, there are several strategies for identifying ecDNA on a whole-genome scale based on sequencing technologies. AmpliconArchitect is an ecDNA identification framework based on whole-genome sequencing (WGS) technology that constructs ecDNA by analyzing the junction relationships between amplified fragments [<xref ref-type="bibr" rid="CR14">14</xref>]. This approach recommends 5–10× WGS data [<xref ref-type="bibr" rid="CR14">14</xref>], which involves many computational resources. An alternative approach is constructing sequencing libraries by digesting linear DNA using exonucleases and enriching circular DNA using a rolling circle amplification (RCA) technique to generate sequencing libraries [<xref ref-type="bibr" rid="CR15">15</xref>]. However, the technical challenges of this approach remain, especially for ecDNA of several megabase pairs long, where the avoidance of circular DNA damage and high-fidelity amplification are critical for success [<xref ref-type="bibr" rid="CR1">1</xref>]. Recently, the Circle_finder method, which uses assay for transposase-accessible chromatin using sequencing (ATAC-Seq) data to discover junctions by collecting supplementary alignment reads, which has been reported to identify small circular DNAs or even ecDNAs [<xref ref-type="bibr" rid="CR16">16</xref>]. However, given the stringent conditions of the supplementary alignment, which limited the number of reads to prove a junction (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1B</xref>), particularly the lack of consideration for continuity between fragments and complex rearrangements, the method cannot detect the complex ecDNA (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1A</xref>). ATAC-Seq is a well-established technique for assessing chromosomal accessibility, using the Tn5 transposase to insert sequencing adapters into open regions of chromosomes to construct a sequencing library [<xref ref-type="bibr" rid="CR17">17</xref>]. It has been shown that ecDNA has less higher-order chromatin compaction compared to DNA on chromosomes and offers significantly enhanced chromatin accessibility, distinguishing them from linear duplication [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Analysis of known ecDNA shows that the ATAC-Seq signals reach a minimum local depth of 80× for ecDNA at an overall sequencing depth of 1–3× (Supplementary Table <xref rid="MOESM8" ref-type="media">S2</xref>). Therefore, we developed circlehunter to reconstruct ecDNA by taking full advantage of the increased ATAC-Seq signals arising from the high accessibility of ecDNA itself. By taking advantage of this feature of ecDNA, we can avoid the RCA step and still enrich for ecDNA sequence. Using simulated data, we demonstrate that circlehunter still has high accuracy for short read lengths and low depth. Using circlehunter, 1312 ecDNA were identified in 94 publicly available historical data of tumor samples, providing a new perspective for studying the oncogenicity of ecDNA.</p>
  </sec>
  <sec id="Sec2" sec-type="results">
    <title>Results</title>
    <sec id="Sec3">
      <title>Principle of identification method</title>
      <p id="Par3">Extensive research has shown that ecDNA has a chromosomal origin [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. DNA damage, such as chromothripsis, breaks chromosomes into small pieces. These linear DNA fragments can be relegated to head-to-tail orientation due to the DNA repair mechanism to form an ecDNA [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR22">22</xref>]. It has been shown that ecDNA has much more open chromatin and shows significantly enhanced chromatin accessibility [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These results imply that the source regions of ecDNA would exhibit consecutive reads enrichment in ATAC-Seq sequencing results. Thus, the identification method can be processed in the following steps. First, the large number of reads from ecDNA segments generated due to the lack of nucleosome packing can be aligned to their chromosomal origin (Fig. <xref rid="Fig1" ref-type="fig">1A, B</xref>). Segments that may form an ecDNA can be identified as consecutive reads enrichment (Fig. <xref rid="Fig1" ref-type="fig">1C</xref>). Discordant reads pair enrich region may link with another segment (Fig. <xref rid="Fig1" ref-type="fig">1C</xref>) and indicate a candidate region contain a breakpoint. So, we can construct a breakpoints graph linked by discordant reads pairs and consecutive enrichment (Fig. <xref rid="Fig1" ref-type="fig">1D</xref>). All possible circular DNA can be searched from the breakpoint graph (Fig. <xref rid="Fig1" ref-type="fig">1F</xref>). To determine the exact breakpoint from the discordant reads pair enriched region but avoid time-consuming realignment, an integrated Bayesian model is used to estimate the precise breakpoints of fragments (Fig. <xref rid="Fig1" ref-type="fig">1E</xref>). The detailed workflow is described in “Materials and methods”. In contrast to the existing circle_finder method, the reads used by circlehunter as evidence cover the entire length of the predicted ecDNA, enabling circlehunter to identify segments that are ligated circularly and discover genetic variants resulting from the ligation (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1A</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Principle of identification method.</title><p><bold>A</bold> Lack of nucleosome-packed ecDNA generates a large number of reads in ATAC-Seq. <bold>B</bold> Reads mapped to genome reference. <bold>C</bold> Identify consecutive enrich regions and discordant read pair enrich regions. <bold>D</bold> Breakpoints graph linked by discordant read pair enrichment and consecutive read enrichment. <bold>E</bold> Bayesian models estimate breakpoints according to discordant read pairs (left) and clipped reads (middle). <bold>F</bold> Reconstruct ecDNA from the breakpoint graph.</p></caption><graphic xlink:href="41389_2023_476_Fig1_HTML" id="d32e445"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Accuracy of circlehunter</title>
      <p id="Par4">To examine the ability of circlehunter to identify circular DNA from the linear genome reference, we tested it using 500 simulated ecDNA randomly selecting chromosomal regions of the human genome. These mock ecDNAs’ length ranges from 5 kb to 10 Mb, and the number of segments ranges from 1 to 50, covering various conditions of ecDNA (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1C, D</xref>). For short reads sequencing, analysis of long structural variants is usually limited by the coverage and read length. We simulated different ecDNA local depth and read-length datasets to check the detection performance of circlehunter under different conditions. We also compared it with the existing tool Circle_finder, which can analyze ecDNA from ATAC-Seq [<xref ref-type="bibr" rid="CR16">16</xref>]. The test result showed that circlehunter could reconstruct the most mock ecDNA in different local depth datasets. Since circlehunter only considers segments linked with significant number of reads, it has higher precision and recall than circle_finder when local depth is less than 10× (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1E–H</xref> and Supplementary Table <xref rid="MOESM7" ref-type="media">S1</xref>). For comparison purposes, we introduce the F1 score to evaluate the detection performance of each tool. The results shown that circlehunter outperforms circle_finder at different local depth levels except with local depth less than 10× (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>, left), with an F1 score of 0.93 at local depth greater than 30×. On this basis, we test the effect of varying read length on the detection performance at the local depth of 30×. The results showed that circlehunter was barely affected by read length, but circle_finder could not obtain any results when the read length was less than 75 bp (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>, right). This is mainly because read length will significantly affect the appearance of supplementary alignment, but not the number of discordant reads pair. This enables circlehunter, which works on discordant read pairs, to be almost independent of read length. Still, the read length affects circlehunter’s estimate of the exact breakpoint, and a shorter read length will result in a larger confidence interval (Fig. <xref rid="Fig2" ref-type="fig">2C</xref>). Since circle_finder reports only those circular DNAs that are generated by end-to-end ligation of one linear fragment, we also generated a test set consisting only single-segment ecDNAs. The results show that circlehunter still outperforms circle_finder for single-segment ecDNA when the coverage is greater than 10× (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>), although circle_finder has better detection performance for single-segment ecDNA test sets than for multi-segment ecDNA test sets (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). These results suggest that circlehunter can accurately detect ecDNA in samples when the local depth of ecDNA is sufficient (&gt;30×). In comparison, the local depth of 11 ecDNAs segments from 6 replicates of 3 known samples was greater than 80× (Supplementary Table <xref rid="MOESM8" ref-type="media">S2</xref>). At this point, the overall depth of the entire genome is between 1–3×, and the overall sequencing depth of most historical samples is also in this interval (Supplementary Fig. <xref rid="MOESM3" ref-type="media">S2C</xref>) (Supplementary Table <xref rid="MOESM9" ref-type="media">S3</xref>). In our collection of historical samples, the sequencing length is usually between 35 and 75 bp (Supplementary Fig. <xref rid="MOESM3" ref-type="media">S2D</xref>) (Supplementary Table <xref rid="MOESM9" ref-type="media">S3</xref>). All can be used as input data for circlehunter. As a negative control, we analyzed 14 ATAC-Seq datasets obtained from normal muscle tissue (Supplementary Table <xref rid="MOESM7" ref-type="media">S1</xref>). Circlehunter only reported 1 ecDNA, demonstrating that it is unlikely to report non-amplified false positives. Also, circlehunter outperforms circle_finder in terms of runtime, memory usage, and IO throughput (Supplementary Fig. <xref rid="MOESM2" ref-type="media">S1I–K</xref>) (Supplementary Table <xref rid="MOESM7" ref-type="media">S1</xref>). These results indicated that circlehunter had high-performance detecting ecDNA and can be applied to most ATAC-Seq data.<fig id="Fig2"><label>Fig. 2</label><caption><title>Accuracy of circlehunter.</title><p><bold>A</bold> F1 score of multi segments ecDNA detection with varying mock ecDNA local depth at 100 bp read length and varying read length at 30× local depth. <bold>B</bold> F1 score of single-segment ecDNA detection with varying mock ecDNA local depth at 100 bp read length and varying read length at 30× local depth. Circlehunter-s: A true-positive result is considered when the circlehunter result covers 95% of the simulated ecDNA and has the same ligation structure; Circlehunter-b: A true-positive result is considered when the circlehunter result breakpoint confidential intervals cover simulated ecDNA breakpoint and have the same ligation structure; Circlefinder-s: A true-positive result is considered when the Circle_finder result covers 95% of the simulated ecDNA. <bold>C</bold> Distribution of 95% confidential interval length with varying read length at 30× local depth. <bold>D</bold>–<bold>F</bold> Identify results of GBM39, PC3, and COLO320DM cell lines. Blue is the validated result, and orange and green are the individual results of two biological replicates. The color of the numbers indicating the genomic position corresponds to the circles. The numbers outside the circles are the absolute positions of the validated ecDNA fragments on the genome. The numbers inside the circles are the errors of the ecDNA fragments identified by circlehunter relative to the validated positions.</p></caption><graphic xlink:href="41389_2023_476_Fig2_HTML" id="d32e529"/></fig></p>
      <p id="Par5">Having observed that we can detect ecDNA from linear genomes in simulation samples, we tried to apply circlehunter to actual samples. Analysis of ATAC-Seq data from three samples with known ecDNA showed that circlehunter could identify ecDNA identified by WGS data and validated by fluorescence in situ hybridization (FISH) [<xref ref-type="bibr" rid="CR6">6</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2D–F</xref>) (Supplementary Table <xref rid="MOESM8" ref-type="media">S2</xref>). The ecDNA in cell line GBM39 has a simple composition, consisting of a long contiguous fragment joined end-to-end with certain deletions in between. Besides minor deletions, circlehunter can accurately identify all breakpoints and their linkage relationships (Fig. <xref rid="Fig2" ref-type="fig">2D</xref>). In contrast, the known ecDNA in the PC3 cell line consists of six fragments joined in multiple ligation directions. However, circlehunter still accurately identifies all ligation relationships and predicts most breakpoints (Fig. <xref rid="Fig2" ref-type="fig">2E</xref>). The most challenging trial was identifying the ecDNA present in COLO320DM, a typical highly chromosomal rearrangement cell line where the ecDNA present may have complex linkage relationships with multiple possible ecDNA. Circlehunter did not identify the known ecDNA identically but identified ecDNA with a similar structure to the known ecDNA in two biological replicates (Fig. <xref rid="Fig2" ref-type="fig">2F</xref>). Based on the priority setting when searching for paths (see “Materials and methods”), we presume the result is an alternative ecDNA present in this sample or computational sub-structure. Overall, test results on both simulated and actual samples show that circlehunter has high accuracy and sensitivity in identifying ecDNA and is generally applicable to regular ATAC-Seq data.</p>
    </sec>
    <sec id="Sec5">
      <title>Application to public data</title>
      <p id="Par6">Based on the high accuracy obtained from simulated and real data testing, we apply circlehunter to publicly available historical data. We curated ATAC-Seq for 547 tumor samples from patient tissues, patient-derived xenografts, and cancer cell lines (Supplementary Fig. <xref rid="MOESM3" ref-type="media">S2A</xref> and Supplementary Table <xref rid="MOESM9" ref-type="media">S3</xref>) from the Gene Expression Omnibus (GEO) database [<xref ref-type="bibr" rid="CR23">23</xref>]. In total, 1312 candidate ecDNA (or microDNA) circular structures were predicted in 94 (17.18%) samples of 17 cancers (Supplementary Table <xref rid="MOESM9" ref-type="media">S3</xref>) by circlehunter. These ecDNAs are sourced from all chromosomes except the Y chromosome (Fig. <xref rid="Fig3" ref-type="fig">3A</xref>) and range in size from 654 to 5,515,037 bp (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>). Half of these ecDNAs are larger than 1 Mb in size (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>), and 97.86% of these ecDNAs are larger than 10 kb, suggesting that these circles are mostly ecDNA-like. The median number of segments that constitute an ecDNA is 6, with a maximum of 18 segments (Fig. <xref rid="Fig3" ref-type="fig">3C</xref>). In terms of cancer types, the most ecDNA was identified in colorectal cancer, prostate cancer, and lung cancer (Fig. <xref rid="Fig3" ref-type="fig">3D</xref>), which have been shown to have recurrent circular amplification [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. ecDNA was present in both primary and metastasis tumor samples, and there was no significant difference in the proportion of both (Supplementary Fig. <xref rid="MOESM3" ref-type="media">S2E</xref>). Therefore, ecDNA may not be inevitably associated with tumor metastasis, but the amplification of genes within ecDNA may still impact tumor metastasis [<xref ref-type="bibr" rid="CR25">25</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><title>Statistics of ecDNAs.</title><p><bold>A</bold> Distribution of ecDNA on chromosomes. <bold>B</bold> Distribution of ecDNA size. <italic>X</italic> axis is log scaled. <bold>C</bold> Distribution of ecDNA segment counts. <bold>D</bold> Distribution of ecDNA-like structure in cancers.</p></caption><graphic xlink:href="41389_2023_476_Fig3_HTML" id="d32e624"/></fig></p>
      <p id="Par7">There is variation in the number of genes contained within each ecDNA (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>), with an average of 10 genes per ecDNA and a total of 251 genes amplified in all ecDNAs. Of these, 37 genes are known to be oncogenes. Certain oncogenes are commonly found on ecDNA and are associated with specific cancers. Three <italic>myc</italic> family genes, <italic>MYC</italic>, <italic>MYCN</italic>, and <italic>MYCL</italic>, are found in ecDNA in various cancers (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). However, <italic>MYC</italic> is usually amplified with <italic>PVT1</italic> (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). While <italic>MYCN</italic>-containing ecDNA is generally found in neuroblastoma, <italic>MYCL</italic>-containing ecDNA is only found in leukemia (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). <italic>EGFR</italic> is only amplified in brain cancer (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). Of the samples that have been analyzed, 109 cell lines have been characterized by the Cancer Cell Line Encyclopedia (CCLE) [<xref ref-type="bibr" rid="CR26">26</xref>]. Using data from the CCLE, we confirmed that ecDNAs predicted by circlehunter have the characteristics of ecDNA, which are consistent with those observed in previous studies [<xref ref-type="bibr" rid="CR9">9</xref>]. In ecDNA, genes typically have higher copy numbers and expression levels and affect cell survival (Supplementary Fig. <xref rid="MOESM4" ref-type="media">S3A–C</xref>). At the same time, the copy number increase of highly expressed genes on ecDNA is correlated with the expression level increase, which is significantly different (<italic>P</italic> = 1.025 × 10<sup>−3</sup>, Fisher transformation z test) from the gene expression level increase driven by other means such as expression regulation (Supplementary Fig. <xref rid="MOESM4" ref-type="media">S3D</xref>). These phenomena are more evident for oncogenes. For example, oncogenes in ecDNA had a significantly high copy number (<italic>P</italic> = 8.754 × 10<sup>−16</sup>, two-sided Wilcoxon rank-sum test) (Fig. <xref rid="Fig4" ref-type="fig">4C</xref>). Similarly, oncogenes contained in ecDNA had significantly higher expression levels at the transcriptional level (<italic>P</italic> = 2.047 × 10<sup>−8</sup>, two-sided Wilcoxon rank-sum test) (Fig. <xref rid="Fig4" ref-type="fig">4D</xref>). Furthermore, knockout of these genes identified as being contained within ecDNA had a significantly greater impact on the growth and survival of the corresponding cells compared to the other cell lines (<italic>P</italic> = 8.408 × 10<sup>−5</sup>, two-sided Wilcoxon rank-sum test) (Fig. <xref rid="Fig4" ref-type="fig">4E</xref>). These characteristics suggest that ecDNA may be an essential driver of cancer. This was confirmed in large-scale clinical data from the PanCancer Analysis of Whole Genomes (PCAWG) project, which showed that genes predicted to have circular amplification were also more likely to be coincident with regions of copy number gain (<italic>P</italic> = 1.619 × 10<sup>−15</sup>, Pearson’s chi-square test) (Fig. <xref rid="Fig4" ref-type="fig">4F</xref>). Similarly, these protein-coding genes, which are predicted to be contained within ecDNA, are also more likely to have somatic mutations (<italic>P</italic> = 4.986 × 10<sup>−2</sup>, Pearson’s chi-square test) (Fig. <xref rid="Fig4" ref-type="fig">4G</xref>). Taken together, these results show that ecDNAs predicted by circlehunter have the typical characteristics of known ecDNAs, which proves the detection performance of circlehunter from the side.<fig id="Fig4"><label>Fig. 4</label><caption><title>Genes contained in ecDNA.</title><p><bold>A</bold> Distribution of genes in ecDNA. <bold>B</bold> Distribution of recurrent oncogenes contained in ecDNA. <bold>C</bold> Kernel density estimate of copy number ascending rank between samples within ecDNA contained the oncogene, and those without ecDNA contained the oncogene. <bold>D</bold> Kernel density estimate of expression level ascending rank between samples within ecDNA contained the oncogene, and those without ecDNA contained the oncogene. <bold>E</bold> Kernel density estimate of gene effect rank between samples within ecDNA contained the oncogene, and those without ecDNA contained the oncogene. <bold>F</bold> Histogram of mean copy number for ecDNA-contained gene and gene never contained in any ecDNA. <bold>G</bold> The fraction of gene mutated in ecDNA-contained gene and gene never contained in any ecDNA.</p></caption><graphic xlink:href="41389_2023_476_Fig4_HTML" id="d32e769"/></fig></p>
    </sec>
    <sec id="Sec6">
      <title>ecDNA in small cell lung cancer (SCLC)</title>
      <p id="Par8">In the results of historical data analysis, we found that in SCLC, ecDNA containing <italic>MYC</italic> (ecMYC) was identified in several samples. SCLC is a highly aggressive subtype that accounts for about 15% of lung cancer cases with a dismal 5-year survival rate of about 6% [<xref ref-type="bibr" rid="CR27">27</xref>]. Amplification of <italic>myc</italic> family genes has been shown to be a characteristic of SCLC [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. A total of 19 ATAC-Seq data from 8 SCLC cell lines is included in the public sample set. We detected ecDNA in 4 SCLC cell lines (Supplementary Table <xref rid="MOESM10" ref-type="media">S4</xref>). Specifically, ecDNA containing <italic>MYCN</italic> was present in NCI-69 (Supplementary Fig. <xref rid="MOESM4" ref-type="media">S3E</xref>). In contrast, ecDNA containing <italic>MYC</italic> and <italic>PVT1</italic> was identified in NCI-H82 (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>), NCI-H2171 (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>), NCI-H524 (Fig. <xref rid="Fig5" ref-type="fig">5C</xref>), and notably, all these ecDNA fragments containing <italic>PVT1</italic>, their breakpoints fall into <italic>PVT1</italic> (Fig. <xref rid="Fig5" ref-type="fig">5A–C</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>MYC amplified on ecDNA.</title><p><bold>A</bold>–<bold>C</bold><italic>MYC</italic> contained ecDNA from NCI-H82, NCI-H2171, and NCI-H524 cell lines. <bold>D</bold> Violin plot of <italic>MYC</italic> copy number from SCLC cell lines. <bold>E</bold>
<italic>MYC</italic> expression level from SCLC cell lines. Significant markers are ns for not significant, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, and ***<italic>P</italic> &lt; 0.001. <bold>F</bold> Relationship between copy number and expression level of <italic>MYC</italic>. Confidence ellipses of ecMYC group (red) and chrMYC (blue) are shown, with confidence intervals represented by ellipses based on three times the standard deviation.</p></caption><graphic xlink:href="41389_2023_476_Fig5_HTML" id="d32e871"/></fig></p>
      <p id="Par9">We focused on examining the amplification of <italic>MYC</italic> on ecDNA. Copy number data from CCLE (NCI-H2107 not included) showed that cell lines with ecMYC had significantly higher copy numbers of the <italic>MYC</italic> than the rest of the SCLC cell lines (<italic>P</italic> = 1.425 × 10<sup>−4</sup>, ANOVA) (Fig. <xref rid="Fig5" ref-type="fig">5D</xref>). At the transcriptional level, <italic>MYC</italic> expression level was significantly higher than the rest of the SCLC cell lines (<italic>P</italic> = 2.327 × 10<sup>−3</sup>, ANOVA) (Fig. <xref rid="Fig5" ref-type="fig">5E</xref>), too. These cell lines were differentiated based on their <italic>MYC</italic> amplification status, with ecMYC exhibiting higher <italic>MYC</italic> copy number and expression levels (Fig. <xref rid="Fig5" ref-type="fig">5F</xref>). Gene Set Enrichment Analysis (GSEA) results showed that target genes of <italic>MYC</italic> were enriched in samples within ecMYC (Fig. <xref rid="Fig6" ref-type="fig">6A</xref>) (Supplementary Table <xref rid="MOESM11" ref-type="media">S5</xref>), demonstrating that <italic>MYC</italic> was amplified on ecDNA in these samples and regulated the transcription level of <italic>MYC</italic> target genes as well. From the results of differentially expressed gene analysis, we obtained 321 genes whose expression levels were significantly different between cell lines with either ecMYC or <italic>MYC</italic> on the chromosome (chrMYC) (Supplementary Fig. <xref rid="MOESM5" ref-type="media">S4A</xref>) (Supplementary Table <xref rid="MOESM11" ref-type="media">S5</xref>). Gene Ontology (GO) analysis revealed that these genes were significantly enriched in pathways associated with developmental regulation and regulation of cell differentiation (Fig. <xref rid="Fig6" ref-type="fig">6B</xref>) (Supplementary Table <xref rid="MOESM11" ref-type="media">S5</xref>), in agreement with the cancer hallmark of SCLC [<xref ref-type="bibr" rid="CR27">27</xref>], suggesting that ecMYC may drive cells to develop specific expression patterns and lead to SCLC. Publicly available transcriptome sequencing data from 81 SCLC specimens indicate that this expression pattern is also observed in patients with high <italic>MYC</italic> expression who are enriched for differentially expressed genes obtained from cell lines (Supplementary Fig. <xref rid="MOESM5" ref-type="media">S4B</xref>). <italic>MYC</italic> and <italic>NEUROD1</italic> were the most highly expressed genes (Supplementary Fig. <xref rid="MOESM5" ref-type="media">S4A</xref>). Despite the paucity of data, we did observe a trend in which <italic>MYC</italic> and <italic>NEUROD1</italic> both affect the survival of cells with ecMYC (Supplementary Fig. <xref rid="MOESM5" ref-type="media">S4C</xref>). Much of the research on SCLC has been conducted that molecular subtypes of SCLC are usually distinguished by the expression level of four subtype factors, including <italic>NEUROD1</italic>, rather than genomic mutations [<xref ref-type="bibr" rid="CR32">32</xref>]. We, therefore, examined the expression of four SCLC subtype factors, and the high <italic>NEUROD1</italic> expression showed that these three cell lines with ecMYC all belong to the SCLC-N (<italic>NEUROD1</italic>) subtype (Fig. <xref rid="Fig6" ref-type="fig">6C</xref>). And the correlation between <italic>MYC</italic> and <italic>NEUROD1</italic> in terms of expression level further suggests a regulatory role of <italic>MYC</italic> on <italic>NEUROD1</italic> (Fig. <xref rid="Fig6" ref-type="fig">6D</xref> and Supplementary Fig. <xref rid="MOESM5" ref-type="media">S4D</xref>). To examine the regulatory effects of ecMYC on <italic>NEUROD1</italic>, we first investigated the accessibility of the transcription start site (TSS) region of the <italic>NEUROD1</italic>, and the data showed that the accessibility of the TSS region of the <italic>NEUROD1</italic> was significantly higher in cell lines with ecMYC than chrMYC (Fig. <xref rid="Fig6" ref-type="fig">6E</xref>). Also, the methylation level of the <italic>NEUROD1</italic> gene was significantly lower on ecMYC cell lines (Fig. <xref rid="Fig6" ref-type="fig">6F</xref>). The presence of enhancers characterized by H3K27ac and H3K4me3 in the TSS of <italic>NEUROD1</italic> was discovered in the epigenomic landscape of the NCI-H2171 cell line with publicly available data (Fig. <xref rid="Fig6" ref-type="fig">6G</xref>). The <italic>MYC</italic> bound to the enhancer provides direct evidence for <italic>MYC</italic> regulation of <italic>NUEROD1</italic> by <italic>MYC</italic> (Fig. <xref rid="Fig6" ref-type="fig">6G</xref>). MED1 and RNA polymerase II signals show that <italic>NEUROD1</italic> transcription is active under the regulation of <italic>MYC</italic> (Fig. <xref rid="Fig6" ref-type="fig">6G</xref>). Together, these results indicate that ecMYC drives the expression pattern of the SCLC-N subtype in SCLC cell lines with ecMYC. Thus, we could relate the expression pattern of SCLC to genomic variation.<fig id="Fig6"><label>Fig. 6</label><caption><title>ecMYC-driven SCLC-N expression pattern.</title><p><bold>A</bold> GSEA result of term HALLMARK_MYC_TARGETS_V2 from MSigDB between SCLC cell lines with ecMYC and chrMYC. <bold>B</bold> GO analysis for differentially expressed genes between cell lines with ecMYC and chrMYC. <bold>C</bold> Heatmap of 4 SCLC subtype factors expression. <bold>D</bold> Correlation between <italic>MYC</italic> and <italic>NEUROD1</italic> expression levels in SCLC cell lines. <bold>E</bold> Accessibility of ecMYC and chrMYC cell lines at <italic>NEUROD1</italic> TSS. <bold>F</bold> The methylation level of the CpG cluster in the <italic>NEUROD1</italic> locus. <bold>G</bold> The epigenomic landscape of the NCIH-2171 cell line in <italic>NEUROD1</italic> locus.</p></caption><graphic xlink:href="41389_2023_476_Fig6_HTML" id="d32e1103"/></fig></p>
      <p id="Par10">In addition to these few cell lines of SCLC, we tried to extend the finding to more samples. Hierarchical clustering analysis based on neuroendocrine markers [<xref ref-type="bibr" rid="CR30">30</xref>] showed that 51 SCLC cell lines were separated into 3 clusters, and all 3 ecMYC-containing cell lines were partitioned into cluster C2 (Fig. <xref rid="Fig7" ref-type="fig">7A</xref>) with high expression of <italic>MYC</italic> (Fig. <xref rid="Fig7" ref-type="fig">7C</xref>) and <italic>NEUROD1</italic> (Fig. <xref rid="Fig7" ref-type="fig">7D</xref>). We also observed a similar pattern of classification in patients (Fig. <xref rid="Fig7" ref-type="fig">7B</xref>). Samples with high levels of <italic>NEUROD1</italic> expression were partitioned to the C2 cluster (Fig. <xref rid="Fig7" ref-type="fig">7B, F</xref>), but unlike the cell lines, the C2 cluster had a lower overall expression of <italic>MYC</italic>. However, they had the highest <italic>MYC</italic> expression individual samples (Fig. <xref rid="Fig7" ref-type="fig">7E</xref>). This could be a sampling bias as most of these samples are limited-stage SCLC, and <italic>MYC</italic> amplification is relatively rare [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Interestingly, we observed that samples from the C1 cluster in either cell lines or patients had high <italic>MYC</italic> and <italic>POU2F3</italic> or <italic>YAP1</italic> expression (Fig. <xref rid="Fig7" ref-type="fig">7B</xref>), suggesting that there may be an association between them or <italic>MYC</italic> drives a greater number of subtypes than just SCLC-N. However, elevated <italic>NEUROD1</italic> expression has been shown to be a clear marker of poor prognosis. Conversely, increased expression of <italic>POU2F3</italic> is indeed a marker of good prognosis [<xref ref-type="bibr" rid="CR35">35</xref>], so the two may have entirely different driving mechanisms. SCLC has been reported to have unique therapeutic vulnerabilities between subtypes, and SCLC-N is sensitive to Aurora kinase inhibitors (AURKi) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. AURKi has been shown to induce degradation of <italic>myc</italic> in hepatocellular carcinomas mice [<xref ref-type="bibr" rid="CR37">37</xref>], so it is reasonable to hypothesize that AURKi is equally effective in SCLC driven by ecMYC. On the basis of drug screening data obtained from the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) databases [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], we observed similar results for cell lines with ecMYC and ecDNA containing <italic>MYCN</italic> that were sensitive to type I AURKi (Fig. <xref rid="Fig7" ref-type="fig">7G</xref> and Supplementary Fig. <xref rid="MOESM4" ref-type="media">S3F</xref>). This result further demonstrates the driving role of ecMYC in these three cell lines. On the other hand, cell lines with amplification of <italic>MYCL</italic> (Supplementary Fig. <xref rid="MOESM4" ref-type="media">S3F</xref>), which is also a member of the <italic>myc</italic> gene family, are insensitive to AURKi (Fig. <xref rid="Fig7" ref-type="fig">7G</xref>). In addition, we also predicted the patient’s response to type I AURKi, and the results showed that the C2 cluster samples were the most sensitive (Fig. <xref rid="Fig7" ref-type="fig">7H</xref>). These results suggest that SCLC-N has unique therapeutic vulnerabilities and may be related to ecMYC.<fig id="Fig7"><label>Fig. 7</label><caption><title>Expression patterns of SCLC subtypes.</title><p><bold>A</bold> Unsupervised hierarchical cluster analysis of neuroendocrine markers from human SCLC cell lines. <bold>B</bold> Unsupervised hierarchical cluster analysis of neuroendocrine markers from human SCLC patients. <bold>C</bold>, <bold>D</bold> The expression level of <italic>MYC</italic> and <italic>NEUROD1</italic> between SCLC cell line clusters. <bold>E</bold>, <bold>F</bold> The expression level of <italic>MYC</italic> and <italic>NEUROD1</italic> between SCLC patient clusters. <bold>G</bold> Heatmap of 7 SCLC cell line response to 11 AURK inhibitors. <bold>H</bold> AURKi response prediction between patient clusters.</p></caption><graphic xlink:href="41389_2023_476_Fig7_HTML" id="d32e1275"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec7" sec-type="discussion">
    <title>Discussion</title>
    <p id="Par11">Since its discovery half a century ago, ecDNA has gradually been recognized as a hallmark of cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. Non-chromosomal inheritance, which drives the amplification of oncogenes on ecDNA, allows tumors to rapidly evolve their genomes, gain a survival advantage and resist to drug treatment [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Existing ecDNA identification methods typically require complex steps of circular DNA enrichment library construction steps or the analysis of large amounts of data. For this reason, circlehunter pipeline, developed for identifying ecDNA using regular ATAC-Seq data, is a necessary complement. Analysis of both simulated and known samples shows that circlehunter has high accuracy in identifying complex circular structures from linear genomes. Our analysis of ATAC-Seq data from 547 tumor samples predicted 1312 ecDNAs in 94 samples. Data from CCLE showed that 37 oncogenes were amplified on ecDNAs, which is consistent with the essential characteristics of ecDNA. These results demonstrate that we could find cancer-associated ecDNA from existing regular ATAC-Seq data and interpret cancer characteristics from a different perspective. For example, ecMYCs were identified in three SCLC cell lines. Genomic and transcriptomic data from publicly available sources indicate that these three cell lines have essential characteristics of ecDNA, including oncogene copy number gain and increased expression levels. Further analysis showed that ecMYC drives these 3 cell lines to exhibit the same expression pattern characteristic of the SCLC-N subtype. Of these, epigenomic data from the NCI-H2171 cell line further supported a regulatory role of ecMYC on <italic>NEUROD1</italic>, an essential factor in the expression pattern of SCLC-N subtypes. Drug screening data showed that these cell lines were sensitive to AURKi, a potential class of drugs targeting <italic>MYC</italic> amplification is a promising drug for treating SCLC patients with ecMYC.</p>
    <p id="Par12">However, there are also disadvantages to using ATAC-Seq data for ecDNA identification. As the sequencing depth obtained by ATAC-Seq is not a direct reflection of the copy number of the original template, without this information, circlehunter can fail to construct circles that contain repeated or foldback segments, such as homogeneously staining region (HSR) and breakage fusion bridge (BFB) cycle. In addition, other complex structural variants that are detectable by bioinformatic tools such as JaBbA [<xref ref-type="bibr" rid="CR40">40</xref>] or LINX [<xref ref-type="bibr" rid="CR41">41</xref>], which utilize depth-balanced junction graphs, may not be identified by circlehunter without this information. Therefore, it is important to note that the current benchmarking strategy has limitations, and we cannot guarantee the accuracy of ecDNA calls for all types of focal amplifications. Future studies should explore the rate at which this happens and devise strategies to improve the accuracy of ecDNA detection for other types of focal amplifications. It has been reported in the literature that copy number profile can be predicted using single-cell ATAC-Seq data [<xref ref-type="bibr" rid="CR42">42</xref>], and the addition of the copy number profile can allow circlehunter to remove some of the computational sub-structure by calculating the copy number balance on either side of the breakpoint. However, the application of circlehunter to single-cell ATAC-Seq data has yet to be explored. At the same time, short read-length sequencing has a natural disadvantage for detecting structural variants, which may lead circlehunter to discover more computational sub-structures, as in the case of the COLO320DM cell line. But no single solution is perfect, and in our scenario, if the copy number of ecDNA has not yet increased to a level at which it can be identified early in the amplification process, this ecDNA becomes difficult to identify using regular WGS data, for example, the AmpliconArchitect software, which requires copy number variation as input. We believe that the circlehunter should still be valid in this instance, given that ecDNA lacks nucleosome wrapping and will yield more library fragments generated by Tn5 cutting, which can be considered a means of enrichment to some degree. We also note that most of the samples in the dataset we analyzed were cell lines, and the proportion of individual cancer types deviated significantly from each other. Additional data are needed to improve our understanding of the possible issues with using ATAC-Seq for ecDNA analysis. As circlehunter is built on the basis that ecDNA has less higher-order compaction than chromosomes. This finding has been reported in large-scale and empirical studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], but more data are needed to support whether all ecDNAs share this characteristic. On the other hand, if other classes of focal amplification have misregulated chromatin, they may be detected as false-positive ecDNA by circlehunter. In closing, we provide a tool to explore cancer-associated ecDNA, utilizing new or existing data, and offer a unique entry point for oncology research.</p>
  </sec>
  <sec id="Sec8" sec-type="materials|methods">
    <title>Materials and methods</title>
    <sec id="Sec9">
      <title>The circlehunter pipeline</title>
      <p id="Par13">The circlehunter pipeline was constructed using snakemake [<xref ref-type="bibr" rid="CR43">43</xref>]. The main steps are as follows (Supplementary Fig. <xref rid="MOESM6" ref-type="media">S5</xref>).</p>
    </sec>
    <sec id="Sec10">
      <title>Preprocess</title>
      <p id="Par14">Input FASTQ files were processed by fastp [<xref ref-type="bibr" rid="CR44">44</xref>] to remove adapter and low-quality bases. Clean reads were mapped to the genome using bwa-mem [<xref ref-type="bibr" rid="CR45">45</xref>]. Duplicated reads were marked by samblaster [<xref ref-type="bibr" rid="CR46">46</xref>] and then transformed into coordinate sorted BAM files using samtools [<xref ref-type="bibr" rid="CR47">47</xref>]. Reads mapped out of ENCODE blacklist [<xref ref-type="bibr" rid="CR48">48</xref>] with a MAPQ &gt; 10 and not marked as duplicates will be kept and used for the next steps.</p>
    </sec>
    <sec id="Sec11">
      <title>Enrich region identify</title>
      <p id="Par15">For consecutive enrich regions, all reads were used as input to call peak using MACS2 [<xref ref-type="bibr" rid="CR49">49</xref>] with parameters --nomodel --nolambda -p 0.05. This implies that all reads will be pileup as depth of each base. The <italic>P</italic> value for each base will then be determined by a Poisson distribution using each base’s depth, with the average depth of the genome as <italic>λ</italic>. Sequential bases with a <italic>P</italic> value &lt; 0.05 will be considered as significant peaks. Peaks with distances less than 12.5 kb will be merged as one consecutive enrich region using bedtools [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
      <p id="Par16">For discordant reads pair enrich regions, discordant read pairs (insert size &gt;1500 bp as default but can be adjusted) were extracted and pileup. Their ratio to the depth of the same base was then calculated. Using a Poisson distribution with the mean ratio of the whole genome as <italic>λ</italic>, the ratio of each base will be computed as a <italic>P</italic> value, similar to consecutive enrich region identification. Consecutive bases with <italic>P</italic> value &lt; 0.05 will stitch as discordant enrich regions. These steps were performed by MACS2 bdgcmp with parameter -m ppois and bdgpeakcall with parameter -c 1.301 <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$( = - \log _{10}0.05)$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>−</mml:mo><mml:mi>log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mn>0.05</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41389_2023_476_Article_IEq1.gif"/></alternatives></inline-formula>. Only regions that overlap with consecutive enriched regions are kept.</p>
    </sec>
    <sec id="Sec12">
      <title>Construct the breakpoint graph</title>
      <p id="Par17">The breakpoints graph relies on MultiGraph in NetworkX [<xref ref-type="bibr" rid="CR51">51</xref>]. All discordant read pair enrich regions are added as nodes. Two types of edges are then added according to enriched regions. Two discordant enrich regions share paired-end reads with the same reads ID, which means a discordant type edge. The user can specify a minimum number of reads IDs with the same mapped orientation that must be present for a discordant edge to be formed. The default setting is the inverse survival of the Poisson model used for enrichment assessment. When a discordant type of edge is added to the graph, the orientation of the reads that support the edge is recorded in both nodes it connects. This direction is used as the extension direction of this node. All nodes properly oriented to one another within one consecutive enrich region will be connected by consecutive type edges.</p>
    </sec>
    <sec id="Sec13">
      <title>Breakpoint estimate</title>
      <p id="Par18">Despite the discordant read pair enrichment region suggesting that a breakpoint is present, it does not provide the precise position of the breakpoint. Hence, we propose a Bayesian model to estimate a more precise breakpoint position. The breakpoint position is estimated by combining two distinct Bayesian models. Circlehunter takes discordant read pairs mapped in the discordant enrich region, because the reads stopping before the breakpoint, so it can only be used to estimate the minimum extended position of the breakpoint. Similar to the German tank problem [<xref ref-type="bibr" rid="CR52">52</xref>], with the innermost base of the discordant reads enriched region as the origin and the distance from each possible breakpoint to the origin as <italic>h</italic>. The probability of observing reads with an end position less than <italic>h</italic> appearing in <italic>L</italic> follows a uniform distribution between 1 and <italic>h</italic>.<disp-formula id="Equa"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_L\left( {L|h} \right) = \left\{ {\begin{array}{*{20}{l}} {0,} \hfill &amp; {{{{\mathrm{if}}}}\,L &gt; h} \hfill \\ {Uniform\left( {1,h} \right),} \hfill &amp; {{{{\mathrm{otherwise}}}}} \hfill \end{array}} \right.$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi>L</mml:mi><mml:mo>∣</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mi mathvariant="normal">if</mml:mi><mml:mspace width="0.25em"/><mml:mi>L</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>h</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mi mathvariant="normal">otherwise</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="41389_2023_476_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par19">The other model is a simple normal distribution, where the reads aligned to the breakpoints will be clipped during the alignment process. Their alignment end position <italic>S</italic> should fall within a small ±<italic>e</italic> distance from the actual breakpoint. Thus, the probability of such reads’ alignment end positions occurring in <italic>S</italic> is observed to obey a normal distribution with <italic>h</italic> as the expectation and <italic>e</italic><sup>2</sup> as the variance.<disp-formula id="Equb"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_S\left( {S|h} \right) = N\left( {h,e^2} \right)$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi>S</mml:mi><mml:mo>∣</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>h</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="41389_2023_476_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par20">Assuming that the probabilities of being observed for these two types of reads are independent, the two model posterior probabilities can be integrated as<disp-formula id="Equc"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\log P\left( {h|L_{1:n},S_{1:m}} \right) = \chi + \mathop {\sum}\limits_{i = 1}^n {\log } P_L\left( {L_i|h} \right) + \mathop {\sum}\limits_{i = 1}^n {\log } P_S\left( {S_i|h} \right)$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mi>log</mml:mi><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>h</mml:mi><mml:mo>∣</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>χ</mml:mi><mml:mo>+</mml:mo><mml:munderover accent="false" accentunder="false"><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mi>log</mml:mi><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:munderover accent="false" accentunder="false"><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mi>log</mml:mi><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∣</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="41389_2023_476_Article_Equc.gif" position="anchor"/></alternatives></disp-formula>where <italic>χ</italic> is the normalized parameters of the model, the maximum-likelihood estimates <inline-formula id="IEq2"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat h$$\end{document}</tex-math><mml:math id="M10"><mml:mover accent="true"><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:math><inline-graphic xlink:href="41389_2023_476_Article_IEq2.gif"/></alternatives></inline-formula> and 95% confidence interval are then obtained from the model through a grid search. The breakpoints estimated by the model will be applied to the breakpoint graph nodes.</p>
    </sec>
    <sec id="Sec14">
      <title>Search ecDNA from the breakpoint graph</title>
      <p id="Par21">The proper ecDNA will be reconstructed from the graph by a modified depth-first search algorithm. Since the breakpoint graph constructed by circlehunter comprises two types of edges connecting different breakpoints, a proper ecDNA circle needs to search along a path with two distinct types of edges. When searching for the next breakpoint by depth-first in the graph, the type of the edge connecting the next breakpoint must not be the same as the type of the edge connecting the prior breakpoint. Circlehunter will first search for segments with greater size and higher local depth to include more genes and to find more reliable ecDNAs. All possible circles and breakpoint confidential intervals will be output in BED format as distinct candidate ecDNA structures. Typically, circlehunter will cover all nodes. However, a minimal number of samples that undergo complex rearrangement will result in many alternative sub-structures, and the user can opt to restrict the output (default as 1000).</p>
    </sec>
    <sec id="Sec15">
      <title>Accuracy of circlehunter</title>
      <p id="Par22">We randomly generated 500 ecDNAs in order to evaluate the accuracy of circlehunter and to compare it to the existing circle_finder approach that can analyze ecDNA from ATAC-Seq data. The sizes of fragments vary from 5 kb to 10 Mb, and the number of fragments in a single ecDNA varies from 1 to 50, covering a wide range of ecDNA conditions. All segments were randomly selected from the GRCh38 not N regions. Each segment is randomly assigned a ligation direction, and sequences are extracted from the genome accordingly. All sequences from the same ecDNA were sequentially ligated into one large circular sequence. Subsequently, pair-end sequencing simulation was performed using art employing the Illumina default profile [<xref ref-type="bibr" rid="CR53">53</xref>]. The ATAC-Seq data of the GM12878 sample (GSE170245) from ENCODE is blended as background with the output of 20 ecDNA sequencing simulations for each run. This will create a sample containing 20 randomly generated ecDNAs, and 25 such samples will be produced in total, resulting in 500 ecDNAs. The simulation method for one-segment ecDNA is the same as that for multi-segment ecDNA except for limiting the number of fragments per ecDNA. ATAC-Seq data for three samples with known ecDNA were downloaded from GEO (Supplementary Table <xref rid="MOESM8" ref-type="media">S2</xref>), with two biological replicates per sample. These samples were analyzed based on the hg19 references.</p>
    </sec>
    <sec id="Sec16">
      <title>Identify ecDNA in historical data</title>
      <p id="Par23">ATAC-Seq data for 547 tumor samples were obtained from the GEO database (Supplementary Table <xref rid="MOESM9" ref-type="media">S3</xref>). Manual curation was conducted on the search results for the term “ATAC-Seq”. Only samples that were identified as being derived from cancer and had not received any special treatment, such as drug or gene modifications, were kept. The FASTQ format raw data were obtained from Sequence Read Archive (SRA) [<xref ref-type="bibr" rid="CR54">54</xref>] using SRA Toolkit. And the analysis was conducted with circlehunter with the hg38 genome as the reference using default settings. Initial results were filtered according to the following conditions: fold enrich &gt;10, discordant reads proof a junction &gt;2, less than 5% of length overlap with RepeatMasker [<xref ref-type="bibr" rid="CR55">55</xref>] repeat regions. Gene annotations were downloaded from UCSC refSeq (refGene) [<xref ref-type="bibr" rid="CR56">56</xref>]. AllOnco (<ext-link ext-link-type="uri" xlink:href="http://www.bushmanlab.org/links/genelists">http://www.bushmanlab.org/links/genelists</ext-link>) cancer gene list curated by Bushman Lab was used as an oncogene list. Copy number, expression level, and gene effect data for cancer cell lines sourced from CCLE [<xref ref-type="bibr" rid="CR26">26</xref>] can be accessed from DepMap (<ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/">https://depmap.org/portal/</ext-link>). Clinical copy number and coding driver mutations from PCAWG were downloaded from Xena [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
    </sec>
    <sec id="Sec17">
      <title>Identify ecDNA in SCLC</title>
      <p id="Par24">Nineteen ATAC-Seq data from 8 SCLC cell lines (Table <xref rid="MOESM10" ref-type="media">S4</xref>) were downloaded from the GEO database and analyzed using hg38 as the reference. Data for copy number and expression level of the gene were obtained from DepMap Public 22Q1. GSEA and GO analyses were performed using GSEAPY (<ext-link ext-link-type="uri" xlink:href="https://github.com/zqfang/GSEApy">https://github.com/zqfang/GSEApy</ext-link>), and the gene sets were downloaded from MSigDB [<xref ref-type="bibr" rid="CR58">58</xref>]. Differently expressed genes were identified using the Student <italic>t</italic> test. Differentially expressed genes between the ecMYC group and chrMYC were defined as the absolute value of log foldchange &gt;2 and <italic>P</italic> value &lt; 0.05. Transcriptome sequencing data of human SCLC tumor samples (<italic>n</italic> = 81) were obtained from published literature [<xref ref-type="bibr" rid="CR33">33</xref>], and SCLC cell lines (<italic>n</italic> = 51) were obtained from CCLE. The log2-FPKM cut-off to distinguish patients as having <italic>MYC</italic> high and <italic>MYC</italic> low is the upper quartile for all patients. The same cut-off value is used to classify cell lines. Epigenomic sequencing data for the NCI-H2171 cell line were downloaded from GEO with accession GSE36354, aligned to the hg38 reference using bwa-mem, pileup as per million reads signal and scaling to the smallest sample using MACS2. Drug screening data were sourced from GDSC [<xref ref-type="bibr" rid="CR38">38</xref>] and CTRP [<xref ref-type="bibr" rid="CR39">39</xref>] and downloaded from DepMap. We used drug response data from oncoPredict’s [<xref ref-type="bibr" rid="CR59">59</xref>] prediction given the large number of missing data in the original screening data. The model was trained using all accessible SCLC screening data and was later used to predict the response of 51 cell lines to 11 AURKi drugs. The response of SCLC patients to AURKi was similarly predicted by oncoPredict.</p>
    </sec>
    <sec id="Sec18">
      <title>Statistical analysis</title>
      <p id="Par25">The statistical methods are described in the corresponding statements and figure legends. Statistical analysis is performed by SciPy or Pingouin in Python.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary information</title>
    <sec id="Sec19">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41389_2023_476_MOESM1_ESM.docx">
            <caption>
              <p>Supplementary lengend</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="41389_2023_476_MOESM2_ESM.pdf">
            <caption>
              <p>Fig. S1</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="41389_2023_476_MOESM3_ESM.pdf">
            <caption>
              <p>Fig. S2</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM4">
          <media xlink:href="41389_2023_476_MOESM4_ESM.pdf">
            <caption>
              <p>Fig. S3</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM5">
          <media xlink:href="41389_2023_476_MOESM5_ESM.pdf">
            <caption>
              <p>Fig. S4</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM6">
          <media xlink:href="41389_2023_476_MOESM6_ESM.pdf">
            <caption>
              <p>Fig. S5</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM7">
          <media xlink:href="41389_2023_476_MOESM7_ESM.xlsx">
            <caption>
              <p>Table S1</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM8">
          <media xlink:href="41389_2023_476_MOESM8_ESM.xlsx">
            <caption>
              <p>Table S2</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM9">
          <media xlink:href="41389_2023_476_MOESM9_ESM.xlsx">
            <caption>
              <p>Table S3</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM10">
          <media xlink:href="41389_2023_476_MOESM10_ESM.xlsx">
            <caption>
              <p>Table S4</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM11">
          <media xlink:href="41389_2023_476_MOESM11_ESM.xlsx">
            <caption>
              <p>Table S5</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary information</title>
    <p>The online version contains supplementary material available at 10.1038/s41389-023-00476-0.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>This work was supported by the National Natural Science Foundation of China (31971117), the National Key R&amp;D Program of China [2018YFA0801100], the Natural Science Foundation of Suzhou [SYS201517], and the Priority Academic Program Development of Jiangsu Higher Education Institutions.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>MY, SC, and MH conceived and designed the study. MY wrote the source code. MY, SZ, and RJ curated data and plotted figures. MY, SZ, RJ, SC, and MH analyzed and interpreted the data. MY, SZ, and RJ wrote the paper. SC and MH supervised the project. All authors approved the final version and agreed to submit the manuscript.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>This study did not generate new data. All publicly available data used are already listed in “Materials and methods” or Supplementary materials.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Code availability</title>
    <p>The source code of circlehunter, including the simulation pipeline and configuration, is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/suda-huanglab/circlehunter">https://github.com/suda-huanglab/circlehunter</ext-link>.</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par26">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bafna</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Mischel</surname>
            <given-names>PS</given-names>
          </name>
        </person-group>
        <article-title>Extrachromosomal DNA: an emerging hallmark in human cancer</article-title>
        <source>Annu Rev Pathol Mech Dis</source>
        <year>2022</year>
        <volume>17</volume>
        <fpage>854744578</fpage>
        <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-051821-114223</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression</article-title>
        <source>Biochim Biophys Acta BBA Rev Cancer</source>
        <year>2020</year>
        <volume>1874</volume>
        <fpage>188392</fpage>
        <pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188392</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bailey</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Shoura</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Mischel</surname>
            <given-names>PS</given-names>
          </name>
          <name>
            <surname>Swanton</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Extrachromosomal DNA-relieving heredity constraints, accelerating tumour evolution</article-title>
        <source>Ann Oncol</source>
        <year>2020</year>
        <volume>31</volume>
        <fpage>884</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.303</pub-id>
        <?supplied-pmid 32275948?>
        <pub-id pub-id-type="pmid">32275948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Helmsauer</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Valieva</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Ali</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chamorro González</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schöpflin</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Röefzaad</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma</article-title>
        <source>Nat Commun</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>5823</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-020-19452-y</pub-id>
        <?supplied-pmid 33199677?>
        <pub-id pub-id-type="pmid">33199677</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morton</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Dogan-Artun</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Faber</surname>
            <given-names>ZJ</given-names>
          </name>
          <name>
            <surname>MacLeod</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bartels</surname>
            <given-names>CF</given-names>
          </name>
          <name>
            <surname>Piazza</surname>
            <given-names>MS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Functional enhancers shape extrachromosomal oncogene amplifications</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>179</volume>
        <fpage>1330</fpage>
        <lpage>1341.e13</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.10.039</pub-id>
        <?supplied-pmid 31761532?>
        <pub-id pub-id-type="pmid">31761532</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Raviram</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Erb</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Santini</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Circular ecDNA promotes accessible chromatin and high oncogene expression</article-title>
        <source>Nature</source>
        <year>2019</year>
        <volume>575</volume>
        <fpage>699</fpage>
        <lpage>703</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-019-1763-5</pub-id>
        <?supplied-pmid 31748743?>
        <pub-id pub-id-type="pmid">31748743</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hung</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Mischel</surname>
            <given-names>PS</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
        </person-group>
        <article-title>Gene regulation on extrachromosomal DNA</article-title>
        <source>Nat Struct Mol Biol</source>
        <year>2022</year>
        <volume>29</volume>
        <fpage>736</fpage>
        <lpage>44</lpage>
        <pub-id pub-id-type="doi">10.1038/s41594-022-00806-7</pub-id>
        <?supplied-pmid 35948767?>
        <pub-id pub-id-type="pmid">35948767</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lubs</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Salmon</surname>
            <given-names>JH</given-names>
          </name>
        </person-group>
        <article-title>The chromosomal complement of human solid tumors: II. Karyotypes of glial tumors</article-title>
        <source>J Neurosurg</source>
        <year>1965</year>
        <volume>22</volume>
        <fpage>160</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.3171/jns.1965.22.2.0160</pub-id>
        <?supplied-pmid 14291674?>
        <pub-id pub-id-type="pmid">14291674</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers</article-title>
        <source>Nat Genet</source>
        <year>2020</year>
        <volume>52</volume>
        <fpage>20</fpage>
        <pub-id pub-id-type="doi">10.1038/s41588-020-0678-2</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kohl</surname>
            <given-names>NE</given-names>
          </name>
          <name>
            <surname>Kanda</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Schreck</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Bruns</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Latt</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Gilbert</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Transposition and amplification of oncogene-related sequences in human neuroblastomas</article-title>
        <source>Cell</source>
        <year>1983</year>
        <volume>35</volume>
        <fpage>359</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="doi">10.1016/0092-8674(83)90169-1</pub-id>
        <?supplied-pmid 6197179?>
        <pub-id pub-id-type="pmid">6197179</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hoff</surname>
            <given-names>DDV</given-names>
          </name>
          <name>
            <surname>Needham-VanDevanter</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Yucel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Windle</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Wahl</surname>
            <given-names>GM</given-names>
          </name>
        </person-group>
        <article-title>Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>1988</year>
        <volume>85</volume>
        <fpage>4804</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.85.13.4804</pub-id>
        <pub-id pub-id-type="pmid">3164477</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nathanson</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Gini</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mottahedeh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Visnyei</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Koga</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Gomez</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA</article-title>
        <source>Science</source>
        <year>2014</year>
        <volume>343</volume>
        <fpage>72</fpage>
        <lpage>76</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1241328</pub-id>
        <?supplied-pmid 24310612?>
        <pub-id pub-id-type="pmid">24310612</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ain</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Schmeer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wengerodt</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Witte</surname>
            <given-names>OW</given-names>
          </name>
          <name>
            <surname>Kretz</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Extrachromosomal circular DNA: current knowledge and implications for CNS aging and neurodegeneration</article-title>
        <source>Int J Mol Sci</source>
        <year>2020</year>
        <volume>21</volume>
        <fpage>2477</fpage>
        <pub-id pub-id-type="doi">10.3390/ijms21072477</pub-id>
        <?supplied-pmid 32252492?>
        <pub-id pub-id-type="pmid">32252492</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Deshpande</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Luebeck</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>N-PD</given-names>
          </name>
          <name>
            <surname>Bakhtiari</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Schwab</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exploring the landscape of focal amplifications in cancer using AmpliconArchitect</article-title>
        <source>Nat Commun</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>392</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-08200-y</pub-id>
        <?supplied-pmid 30674876?>
        <pub-id pub-id-type="pmid">30674876</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paulsen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Koseoglu</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Dutta</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Discoveries of extrachromosomal circles of DNA in normal and tumor cells</article-title>
        <source>Trends Genet</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>270</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tig.2017.12.010</pub-id>
        <?supplied-pmid 29329720?>
        <pub-id pub-id-type="pmid">29329720</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kiran</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Saha</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Paulsen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Chatrath</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ATAC-seq identifies thousands of extrachromosomal circular DNA in cancer and cell lines</article-title>
        <source>Sci Adv</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>eaba2489.</fpage>
        <pub-id pub-id-type="doi">10.1126/sciadv.aba2489</pub-id>
        <?supplied-pmid 32440553?>
        <pub-id pub-id-type="pmid">32440553</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Powell</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Curtis</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>NC</given-names>
          </name>
        </person-group>
        <article-title>From reads to insight: a Hitchhiker’s guide to ATAC-seq data analysis</article-title>
        <source>Genome Biol</source>
        <year>2020</year>
        <volume>21</volume>
        <fpage>22</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-020-1929-3</pub-id>
        <?supplied-pmid 32014034?>
        <pub-id pub-id-type="pmid">32014034</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Storlazzi</surname>
            <given-names>CT</given-names>
          </name>
          <name>
            <surname>Lonoce</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guastadisegni</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Trombetta</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>D’Addabbo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Daniele</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure</article-title>
        <source>Genome Res</source>
        <year>2010</year>
        <volume>20</volume>
        <fpage>1198</fpage>
        <lpage>206</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.106252.110</pub-id>
        <?supplied-pmid 20631050?>
        <pub-id pub-id-type="pmid">20631050</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stephens</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Greenman</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bignell</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Mudie</surname>
            <given-names>LJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Massive genomic rearrangement acquired in a single catastrophic event during cancer development</article-title>
        <source>Cell</source>
        <year>2011</year>
        <volume>144</volume>
        <fpage>27</fpage>
        <lpage>40</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2010.11.055</pub-id>
        <?supplied-pmid 21215367?>
        <pub-id pub-id-type="pmid">21215367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>C-Z</given-names>
          </name>
          <name>
            <surname>Spektor</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cornils</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Francis</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Jackson</surname>
            <given-names>EK</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Chromothripsis from DNA damage in micronuclei</article-title>
        <source>Nature</source>
        <year>2015</year>
        <volume>522</volume>
        <fpage>179</fpage>
        <lpage>84</lpage>
        <pub-id pub-id-type="doi">10.1038/nature14493</pub-id>
        <?supplied-pmid 26017310?>
        <pub-id pub-id-type="pmid">26017310</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leibowitz</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C-Z</given-names>
          </name>
          <name>
            <surname>Pellman</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Chromothripsis: a new mechanism for rapid karyotype evolution</article-title>
        <source>Annu Rev Genet</source>
        <year>2015</year>
        <volume>49</volume>
        <fpage>183</fpage>
        <lpage>211</lpage>
        <pub-id pub-id-type="doi">10.1146/annurev-genet-120213-092228</pub-id>
        <?supplied-pmid 26442848?>
        <pub-id pub-id-type="pmid">26442848</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ly</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Brunner</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Shoshani</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Lan</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Pyntikova</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements</article-title>
        <source>Nat Genet</source>
        <year>2019</year>
        <volume>51</volume>
        <fpage>705</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-019-0360-8</pub-id>
        <?supplied-pmid 30833795?>
        <pub-id pub-id-type="pmid">30833795</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <mixed-citation publication-type="other">Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–10.</mixed-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <mixed-citation publication-type="other">Turner KM. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017;543:122–5.</mixed-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <mixed-citation publication-type="other">Wei J, Wu C, Meng H, Li M, Niu W, Zhan Y, et al. The biogenesis and roles of extrachromosomal oncogene involved in carcinogenesis and evolution. Am J Cancer Res. 2020;10:3532.</mixed-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barretina</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Caponigro</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Stransky</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Venkatesan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Margolin</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>483</volume>
        <fpage>603</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11003</pub-id>
        <?supplied-pmid 22460905?>
        <pub-id pub-id-type="pmid">22460905</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rudin</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Brambilla</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Faivre-Finn</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sage</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Small-cell lung cancer</article-title>
        <source>Nat Rev Dis Prim</source>
        <year>2021</year>
        <volume>7</volume>
        <fpage>3</fpage>
        <pub-id pub-id-type="doi">10.1038/s41572-020-00235-0</pub-id>
        <?supplied-pmid 33446664?>
        <pub-id pub-id-type="pmid">33446664</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <mixed-citation publication-type="other">Nau MM, Carney DN, Battey J, Johnson B, Little C, Gazdar A, et al. Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. In: Potter M, Melchers F, Weigert M, editors. Oncogenes in B-cell neoplasia. Berlin, Heidelberg: Springer Berlin Heidelberg; 1984. p. 172–5.</mixed-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>D-W</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Basom</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genetic requirement for <italic>Mycl</italic> and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer</article-title>
        <source>Genes Dev</source>
        <year>2016</year>
        <volume>30</volume>
        <fpage>1289</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.279307.116</pub-id>
        <?supplied-pmid 27298335?>
        <pub-id pub-id-type="pmid">27298335</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mollaoglu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Guthrie</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Böhm</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Brägelmann</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Can</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Ballieu</surname>
            <given-names>PM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition</article-title>
        <source>Cancer Cell</source>
        <year>2017</year>
        <volume>31</volume>
        <fpage>270</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2016.12.005</pub-id>
        <?supplied-pmid 28089889?>
        <pub-id pub-id-type="pmid">28089889</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Böttger</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Semenova</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>J-Y</given-names>
          </name>
          <name>
            <surname>Ferone</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>van der Vliet</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cozijnsen</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer</article-title>
        <source>Cell Rep</source>
        <year>2019</year>
        <volume>27</volume>
        <fpage>3345</fpage>
        <lpage>3358.e4</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.057</pub-id>
        <?supplied-pmid 31189116?>
        <pub-id pub-id-type="pmid">31189116</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rudin</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Poirier</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Byers</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Dive</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dowlati</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data</article-title>
        <source>Nat Rev Cancer</source>
        <year>2019</year>
        <volume>19</volume>
        <fpage>289</fpage>
        <lpage>97</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-019-0133-9</pub-id>
        <?supplied-pmid 30926931?>
        <pub-id pub-id-type="pmid">30926931</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>George</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Jang</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Cun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ozretić</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comprehensive genomic profiles of small cell lung cancer</article-title>
        <source>Nature</source>
        <year>2015</year>
        <volume>524</volume>
        <fpage>47</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1038/nature14664</pub-id>
        <?supplied-pmid 26168399?>
        <pub-id pub-id-type="pmid">26168399</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gay</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Diao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Groves</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Heeke</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities</article-title>
        <source>Cancer Cell</source>
        <year>2021</year>
        <volume>39</volume>
        <fpage>346</fpage>
        <lpage>360.e7</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.014</pub-id>
        <?supplied-pmid 33482121?>
        <pub-id pub-id-type="pmid">33482121</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <mixed-citation publication-type="other">Megyesfalvi Z, Barany N, Lantos A, Valko Z, Pipek O, Lang C, et al. Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study. J Pathol. 2022;257:674–86.</mixed-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Owonikoko</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nackaerts</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Csoszi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ostoros</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mark</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses</article-title>
        <source>J Thorac Oncol</source>
        <year>2020</year>
        <volume>15</volume>
        <fpage>274</fpage>
        <lpage>87</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jtho.2019.10.013</pub-id>
        <?supplied-pmid 31655296?>
        <pub-id pub-id-type="pmid">31655296</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dauch</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rudalska</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cossa</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Nault</surname>
            <given-names>J-C</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>T-W</given-names>
          </name>
          <name>
            <surname>Wuestefeld</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer</article-title>
        <source>Nat Med</source>
        <year>2016</year>
        <volume>22</volume>
        <fpage>744</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.4107</pub-id>
        <?supplied-pmid 27213815?>
        <pub-id pub-id-type="pmid">27213815</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Soares</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Greninger</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Edelman</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Lightfoot</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Forbes</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>
        <source>Nucleic Acids Res</source>
        <year>2012</year>
        <volume>41</volume>
        <fpage>D955</fpage>
        <lpage>D961.</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id>
        <?supplied-pmid 23180760?>
        <pub-id pub-id-type="pmid">23180760</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rees</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Seashore-Ludlow</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Cheah</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Adams</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Price</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>
        <source>Nat Chem Biol</source>
        <year>2016</year>
        <volume>12</volume>
        <fpage>109</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.1986</pub-id>
        <?supplied-pmid 26656090?>
        <pub-id pub-id-type="pmid">26656090</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hadi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Behr</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Deshpande</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Xanthopoulakis</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs</article-title>
        <source>Cell</source>
        <year>2020</year>
        <volume>183</volume>
        <fpage>197</fpage>
        <lpage>210.e32</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.006</pub-id>
        <?supplied-pmid 33007263?>
        <pub-id pub-id-type="pmid">33007263</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shale</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cameron</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Baber</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cowley</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Papenfuss</surname>
            <given-names>AT</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Unscrambling cancer genomes via integrated analysis of structural variation and copy number</article-title>
        <source>Cell Genomics</source>
        <year>2022</year>
        <volume>2</volume>
        <fpage>100112</fpage>
        <pub-id pub-id-type="doi">10.1016/j.xgen.2022.100112</pub-id>
        <?supplied-pmid 36776527?>
        <pub-id pub-id-type="pmid">36776527</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Nikolic A, Singhal D, Ellestad K, Johnston M, Shen Y, Gillmor A, et al. Copy-scAT: deconvoluting single-cell chromatin accessibility of genetic subclones in cancer. Sci Adv. 2021;7:eabg6045.</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mölder</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Jablonski</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Letcher</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Tomkins-Tinch</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Sochat</surname>
            <given-names>V</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sustainable data analysis with Snakemake</article-title>
        <source>F1000Research</source>
        <year>2021</year>
        <volume>10</volume>
        <fpage>33</fpage>
        <pub-id pub-id-type="doi">10.12688/f1000research.29032.2</pub-id>
        <?supplied-pmid 34035898?>
        <pub-id pub-id-type="pmid">34035898</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>i884</fpage>
        <lpage>90.</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty560</pub-id>
        <?supplied-pmid 30423086?>
        <pub-id pub-id-type="pmid">30423086</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <mixed-citation publication-type="other">Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv13033997 Q-Bio 2013 [Preprint]. 2013. <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1303.3997">http://arxiv.org/abs/1303.3997</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Faust</surname>
            <given-names>GG</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>IM</given-names>
          </name>
        </person-group>
        <article-title>SAMBLASTER: fast duplicate marking and structural variant read extraction</article-title>
        <source>Bioinformatics</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>2503</fpage>
        <lpage>5</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu314</pub-id>
        <?supplied-pmid 24812344?>
        <pub-id pub-id-type="pmid">24812344</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Handsaker</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Wysoker</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fennell</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ruan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Homer</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Sequence Alignment/Map format and SAMtools</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>2078</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id>
        <?supplied-pmid 19505943?>
        <pub-id pub-id-type="pmid">19505943</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amemiya</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Kundaje</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Boyle</surname>
            <given-names>AP</given-names>
          </name>
        </person-group>
        <article-title>The ENCODE Blacklist: identification of problematic regions of the genome</article-title>
        <source>Sci Rep</source>
        <year>2019</year>
        <volume>9</volume>
        <fpage>9354</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-019-45839-z</pub-id>
        <?supplied-pmid 31249361?>
        <pub-id pub-id-type="pmid">31249361</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Eeckhoute</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Bernstein</surname>
            <given-names>BE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Model-based analysis of ChIP-Seq (MACS)</article-title>
        <source>Genome Biol</source>
        <year>2008</year>
        <volume>9</volume>
        <fpage>R137</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id>
        <?supplied-pmid 18798982?>
        <pub-id pub-id-type="pmid">18798982</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Quinlan</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>IM</given-names>
          </name>
        </person-group>
        <article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>841</fpage>
        <lpage>2</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id>
        <?supplied-pmid 20110278?>
        <pub-id pub-id-type="pmid">20110278</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <mixed-citation publication-type="other">Hagberg AA, Schult DA, Swart PJ. Exploring network structure, dynamics, and function using NetworkX. Los Alamos, NM: Los Alamos National Lab. (LANL); 2008. p. 11–16.</mixed-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Goodman</surname>
            <given-names>LA</given-names>
          </name>
        </person-group>
        <article-title>Some practical techniques in serial number analysis</article-title>
        <source>J Am Stat Assoc</source>
        <year>1954</year>
        <volume>49</volume>
        <fpage>97</fpage>
        <lpage>112</lpage>
        <pub-id pub-id-type="doi">10.1080/01621459.1954.10501218</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Myers</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Marth</surname>
            <given-names>GT</given-names>
          </name>
        </person-group>
        <article-title>ART: a next-generation sequencing read simulator</article-title>
        <source>Bioinformatics</source>
        <year>2012</year>
        <volume>28</volume>
        <fpage>593</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr708</pub-id>
        <?supplied-pmid 22199392?>
        <pub-id pub-id-type="pmid">22199392</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leinonen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Sugawara</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shumway</surname>
            <given-names>M</given-names>
          </name>
          <collab>on behalf of the International Nucleotide Sequence Database Collaboration.</collab>
        </person-group>
        <article-title>The sequence read archive</article-title>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>D19</fpage>
        <lpage>21.</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq1019</pub-id>
        <?supplied-pmid 21062823?>
        <pub-id pub-id-type="pmid">21062823</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jurka</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Repbase update: a database and an electronic journal of repetitive elements</article-title>
        <source>Trends Genet</source>
        <year>2000</year>
        <volume>16</volume>
        <fpage>418</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1016/S0168-9525(00)02093-X</pub-id>
        <?supplied-pmid 10973072?>
        <pub-id pub-id-type="pmid">10973072</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pruitt</surname>
            <given-names>KD</given-names>
          </name>
        </person-group>
        <article-title>NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins</article-title>
        <source>Nucleic Acids Res</source>
        <year>2004</year>
        <volume>33</volume>
        <fpage>D501</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gki025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Goldman</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Craft</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hastie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Repečka</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>McDade</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kamath</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Visualizing and interpreting cancer genomics data via the Xena platform</article-title>
        <source>Nat Biotechnol</source>
        <year>2020</year>
        <volume>38</volume>
        <fpage>675</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1038/s41587-020-0546-8</pub-id>
        <?supplied-pmid 32444850?>
        <pub-id pub-id-type="pmid">32444850</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The Gene Ontology Consortium</collab>
          <name>
            <surname>Carbon</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Douglass</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Good</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Unni</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>NL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Gene Ontology resource: enriching a GOld mine</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D325</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1113</pub-id>
        <pub-id pub-id-type="pmid">33290552</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maeser</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gruener</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>RS</given-names>
          </name>
        </person-group>
        <article-title>oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data</article-title>
        <source>Brief Bioinform</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>bbab260</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbab260</pub-id>
        <?supplied-pmid 34260682?>
        <pub-id pub-id-type="pmid">34260682</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
